Focus on Asthma Care

Back to articles

Mepolizumab for eosinophilic asthma

KEY POINT

Results from two small, randomized, double-blind studies showed that monthly I.V. infusions of mepolizumab (Bosatria—GlaxoSmithKline) 750 mg reduced the frequency of severe asthma exacerbations and improved quality of life in patients with refractory eosinophilic asthma with a history of recurrent severe exacerbations (trial 1) and was associated with a significant reduction in prednisone requirements for patients who had asthma with sputum eosinophilia (trial 2).

SOURCES

Haldar P et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–84. 

Nair P et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–93. 

Wenzel SE. Eosinophils in asthma—closing the loop or opening the door? N Engl J Med. 2009;360:1026–8.